| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
182.32(B) |
| Last
Volume: |
9,644,407 |
Avg
Vol: |
2,722,478 |
| 52
Week Range: |
$214.27 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
14,213 |
23,771 |
45,603 |
| Total Sell Value |
$662,802 |
$3,963,214 |
$6,471,520 |
$11,852,673 |
| Total People Sold |
1 |
2 |
3 |
6 |
| Total Sell Transactions |
1 |
3 |
4 |
10 |
| End Date |
2024-02-06 |
2023-11-05 |
2023-05-07 |
2022-05-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-05-05 |
4 |
D |
$231.89 |
$3,710 |
D/D |
(16) |
9,966 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-05-05 |
4 |
D |
$231.89 |
$483,027 |
D/D |
(2,083) |
641,734 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$142,054 |
D/D |
(602) |
40,165 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$13,450 |
D/D |
(57) |
7,604 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$14,630 |
D/D |
(62) |
14,278 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$675,582 |
D/D |
(2,863) |
643,817 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$193,259 |
D/D |
(819) |
54,708 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$13,450 |
D/D |
(57) |
7,620 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$202,698 |
D/D |
(859) |
54,489 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-05-03 |
4 |
D |
$235.97 |
$168,955 |
D/D |
(716) |
64,161 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-05-02 |
4 |
D |
$235.97 |
$4,719 |
D/D |
(20) |
9,982 |
|
- |
|
| Louie Linda H. |
VP, Finance & CAO |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
423 |
10,002 |
|
- |
|
| Graham Jonathan P |
EVP, Gen. Counsel & Secy. |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,390 |
40,767 |
|
- |
|
| Miller Derek |
SVP, Human Resources |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,101 |
7,661 |
|
- |
|
| Grygiel Nancy A. |
SVP & CCO |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
635 |
14,340 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
13,486 |
646,680 |
|
- |
|
| Reese David M |
EVP, Research and Development |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,814 |
55,527 |
|
- |
|
| Khosla Rachna |
SVP, Business Development |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
593 |
7,677 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,237 |
55,348 |
|
- |
|
| Griffith Peter H. |
EVP & CFO |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,814 |
32,598 |
|
- |
|
| Santos Esteban |
EVP, Operations |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,559 |
64,877 |
|
- |
|
| Holley Charles M |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
170 |
7,040 |
|
- |
|
| Ishrak Omar |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
138 |
2,462 |
|
- |
|
| Drake Michael V |
Director |
• • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
138 |
961 |
|
- |
|
| Gordon Murdo |
EVP, Global Commercial Ops |
• • – |
2023-04-30 |
4 |
D |
$239.74 |
$174,531 |
D/D |
(728) |
51,111 |
|
- |
|
2168 Records found
|
|
Page 4 of 87 |
|
|
32.90 (11.82%) 
